Lymphatic PD-L1 Expression Restricts Tumor-Specific CD8⁺ T-cell Responses

Area of Science:

• Immunology
• Cancer Biology
• Cell Biology

Background:

• Lymphatic endothelial cells (LECs) in lymph nodes are crucial for peripheral tolerance.
• LECs constitutively express PD-L1 (CD274), a T-cell inhibitory molecule.
• The role of PD-L1 on tumor-associated LECs in cancer immunity remains unclear.

Purpose of the Study:

• To investigate the function of lymphatic PD-L1 in tumor immunity.
• To determine the impact of lymphatic PD-L1 on T-cell responses and tumor growth.
• To elucidate the mechanism by which lymphatic PD-L1 affects anti-tumor immunity.

Main Methods:

• Generation of a mouse model lacking PD-L1 specifically in lymphatic endothelial cells.
• Challenging these mice with orthotopic B16F10 melanoma and MC38 colorectal carcinoma models.
• Analysis of tumor-specific CD8+ T cell expansion, tumor growth, and adoptive T-cell therapy efficacy.

Main Results:

• Lymphatic PD-L1 deficiency led to increased tumor-specific CD8+ T cell expansion in tumor-draining lymph nodes.
• Reduced primary tumor growth was observed in the MC38 model.
• Enhanced efficacy of adoptive T-cell therapy in the B16F10 model.
• Lymphatic PD-L1 was found to induce apoptosis in tumor-specific CD8+ central memory T cells.

Conclusions:

• Lymphatic endothelial PD-L1 restrains anti-tumor immunity.
• This mechanism involves the induction of apoptosis in tumor-specific CD8+ central memory T cells.
• These findings may explain responses to PD-L1/PD-1 immunotherapy in some cancer patients.